ARTMS in the News

ARTMS Inc. submits Drug Master File for the first ever multi-Curie production of Gallium-68 with ARTMS’ Solid Target Solution on medical cyclotrons

Burnaby, Canada, March 31, 2021 – ARTMS Inc. (ARTMS) is pleased to announce the submission of a Drug Master File (DMF) to the FDA for the high-volume production of Gallium-68 (68Ga) with ARTMS’ solid target technology in combination with a medical cyclotron.  ARTMS’ proprietary QUANTM Irradiation system (QISTM) demonstrated world record production of over 10 […] Read More

ARTMS to Advance ImmunoPET Imaging Isotope with Funding Support from Innovate BC

Vancouver, British Columbia. – March 2, 2021 – ARTMS Inc., the global leader in the development and commercialization of novel technologies and products enabling cyclotron production of the world’s most needed medical radioisotopes, is pleased to announce that it received $300,000 funding from Innovate BC as part of its Ignite program. The funding will be combined […] Read More

ARTMS and Isotopia Molecular Imaging Announce Successful Multi-Curie Labeling of PSMA-11 with Cyclotron Produced Ga-68 Utilizing the QUANTM Irradiation System and Solid Targets

Burnaby, Canada and Petach Tikva, Israel, January 19, 2021 – ARTMS Inc. (ARTMS) and Isotopia Molecular Imaging (Isotopia) are pleased to announce the successful radiolabeling of Isotopia’s prostate cancer imaging kit product, PSMA-11, with over 2 Ci of cyclotron-produced Gallium-68 (68Ga) using ARTMS’ proprietary Quantum Irradiation System™ (QIS™) solid target system. The specially designed Prostate-Specific […] Read More

ARTMS and Telix Pharmaceuticals Announce Successful Production of PSMA-11 with Cyclotron Produced Ga-68 from a Solid Target

Burnaby, Canada and Indianapolis, USA, January 12, 2021 – ARTMS Inc. (‘ARTMS’) and Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’) are pleased to announce they have successfully produced Telix’s prostate cancer imaging product, TLX591-CDx (Kit for the preparation of 68Ga-PSMA-11)[1], using multi-Curie quantities of cyclotron-produced Gallium-68 (68Ga) via ARTMS’ proprietary Quantum Irradiation System (QIS®) solid target […] Read More

Health Canada Approves Cyclotron Produced Technetium-99m utilizing the ARTMS QIS and Solid Targets

Burnaby, Canada, December 22, 2020 – ARTMS Inc. (ARTMS) is excited to announce Health Canada’s marketing approval of cyclotron produced technetium-99m (99mTc) for clinical use.  For the Health Canada submission, ARTMS provided technical expertise and the solid targets required for production to a Canadian consortium consisting of BC Cancer, TRIUMF, Lawson Health Research and the […] Read More

ARTMS Announces New Appointments to Executive Leadership Team

Company adds experienced executives to support the continued expansion of commercial activities and focus on radiopharmaceutical innovator and manufacturer relationships Read More

ARTMS Closes a US$19 Million Series A Financing with Deerfield and Global Health Sciences (GHS) Fund

VANCOUVER, British Columbia, May 19, 2020—ARTMS Inc. a global leader in developing technology that transforms the production of the world’s most-used diagnostic imaging isotopes, today announced that it has raised US$19 million in a Series A financing. The investment was led by Deerfield Management Company with continued investment from seed investor GHS Fund (Quark Venture […] Read More

ARTMS and Telix Pharmaceuticals Announce Manufacturing Collaboration

VANCOUVER, British Columbia and MELBOURNE, Australia, May 06, 2020 (GLOBE NEWSWIRE) — ARTMS Products Inc. (ARTMS), a global leader in the development of novel technologies enabling the production of the world’s highest demand diagnostic imaging isotopes, and Telix Pharmaceuticals Limited (Telix), a clinical-stage biopharmaceutical company developing diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR) […] Read More

Multi-curie production of gallium-68 on a biomedical cyclotron and automated radiolabelling of PSMA-11 and DOTATATE

ARTMS Technology Featured in European Journal of Nuclear Medicine and Molecular Imaging Radiopharmacy and Chemistry Read More

Global News – Metro Vancouver company makes advance in medical isotope technology

A Vancouver-area company has developed new technology to make it possible for hospital-based and other medical cyclotrons to produce Technetium-99, a key isotope for health care. Read More

Cyclotron-based gallium-68 generator breaks production records

26 Nov 2019 Tami Freeman Gallium-68 (68Ga) is a positron emitter that’s becoming established as a valuable diagnostic isotope, primarily for detection of neuroendocrine tumours (NETs). Such tumours do not metabolize glucose well – precluding their visualization via standard FDG-PET scans – but overexpress somatostatin receptors that bind, for example, to the PET agent 68Ga-Dotatate. […] Read More

Competition heats up to produce medical radioisotope

15 Nov 2019 David Kramer Two North American companies hope their novel production processes for technetium-99m give them a leg up in an increasingly crowded market. The global supply chain for the world’s most-used radioisotope, the medical imaging tracer technetium-99m, is notoriously unreliable. When one or more of the handful of reactors producing 99mTc’s parent isotope, molybdenum-99, […] Read More

ARTMS/Odense University Hospital to Present Solid Target Gallium-68 Production Record at European Association of Nuclear Medicine

Found and Chief Technology Officer, Dr. Paul Schaffer, of ARTMS Products Inc., Vancouver, British Columbia – October 10, 2019 – Utilizing the ARTMS QUANTM Irradiation System (QISTM) and collaborating with scientists and clinical researchers from the Odense University Hospital (OUH) and the University of Southern Denmark, ARTMS Products Inc, has demonstrated record gallium-68 (68Ga) production […] Read More

Chuck Conroy Appointed CEO of ARTMS

Charles S. Conroy Chief Executive Officer of ARTMS Products Inc., Vancouver, British Columbia – September 10, 2019 – ARTMS Products Inc., the global leader in the innovation and commercialization of novel technologies that enable cyclotron production of the world’s most needed medical radioisotopes, is pleased to announce the appointment of Charles S. Conroy R.Ph, MBA as […] Read More

ARTMS’ QUANTM Irradiation SystemTM to be featured at two international conferences in September

ARTMS invited presentations in September Vancouver, September 24, 2018 /BusinessWire/ — ARTMS Products, Inc. announced today that it has been invited to present at the National Nuclear Security Administration’s 2018 Mo-99 Topical Meeting on Tuesday, September 25th and the Third International Symposium on Technetium and other Radiometals in Chemistry and Medicine on Thursday, September 27th. Lead […] Read More

QUANTM Irradiation System™ Earns CE Mark Approval

First-in-class, advanced technology enables production of high-value radioisotopes on medical cyclotrons VANCOUVER, August 8, 2018 — ARTMS Products today announced it received CE marking approval for its first-in-class, advanced technology QUANTM Irradiation System TM for producing high-value radioisotopes, such as Tc-99m and Ga-68, on medical cyclotrons. Cyclotron facilities are constantly facing higher isotope costs and […] Read More

ARTMS Products Inc. Raises US$3 Million to Advance a Safe Alternative Way to Locally Produce Medical Isotopes and Avoid Future Supply Distruptions

Vancouver, British Columbia. – December 18, 2017 – Today, ARTMS Products Inc., the leader in the development of novel technologies which enable the production of the world’s most-used diagnostic imaging isotope, announced it has raised US$3 million.  The investment comes from Quark Venture Inc. and GF Securities, through their Global Health Science Fund, which invests […] Read More

ARTMS Products Inc. and GE Healthcare Team up to Expand Cyclotron Produced Radioisotopes and Address Longstanding Radiopharmaceutical Supply Concerns in Medical Imaging

Today, ARTMS Products, Inc. announced they have signed a strategic partnership with GE Healthcare around ARTMS’ proprietary QUANTM99TM Irradiation System (QISTM) for radioisotope production. The goal of the partnership is to supply equipment, technologies and research that supports the production and processing of radioisotopes on GE’s PETtraceTM 800 platform of medical cyclotrons. The QISTM integrates […] Read More

ARTMS Products Inc. Honoured with ‘Most Promising Pre-Commercial Technology’ Award at BC Technology Impact Awards

ARTMS Products, Inc., a Vancouver-based medical technology company, has won ‘Most Promising Pre-Commercial Technology’ at the BC Tech Technology Impact Awards recently held in Vancouver. Chosen from a very competitive pool of companies from diverse areas of industry, this distinction is granted to the company poised to drive fundamental change in their industry within the […] Read More

ARTMS Products Inc. Partners with Alliance Medical to Modernize, Stabilize UK Medical Isotope Supply Chain

ARTMS Products, Inc., a Vancouver-based medical technology company, is pleased to announce that it has entered into a strategic partnership with Alliance Medical to enable and demonstrate an alternative, non-reactor supply of technetium-99m (Tc-99m) within the United Kingdom. ARTMS will provide to Alliance the hardware, know-how, and proprietary consumables to gain regulatory marketing approval within […] Read More